Page 1,651«..1020..1,6501,6511,6521,653..1,6601,670..»

UNL’s new College Diabetes Network hopes to raise awareness, connect students – Daily Nebraskan

Posted: March 7, 2017 at 8:44 am

Most people can think of one person they know who suffers from diabetes, and yet not everyone knows about the disease.

The University of Nebraska-Lincolns College Diabetes Network is setting out to bring awareness to the disease and to promote a supporting environment for diabetics. College Diabetes Network is a nationally Recognized Student Organization that got its start at UNL after Haley Schepers, president and founder of UNLs chapter, decided to bring it here in December 2016. The club was approved in January 2017.

Type 1 diabetes is a disease in which the pancreas stops working, affecting the production of insulin, a hormone that breaks down sugars in the body. Diabetics must use insulin shots or pumps to regulate their blood sugar levels all day every day. Type 1 is an autoimmune disease that has no known cause or cure, although has some hopethere is a cure.

Schepers and the vice president of UNLs College Diabetes Network Ansley Alberts have similar stories about why theyre dedicated to diabetes. Both have younger siblings who were diagnosed at a young age with Type 1 diabetes. Schepers sister was diagnosed at age 12, and Alberts brother was diagnosed at age 11.

Its a complete life cycle change, so being a sister to someone with diabetes is really about being a support system, Alberts said. Its always on your mind.

Now, both students are making it their goal to raise awareness about Type 1 diabetes and to change the culture on campus. They want the club to be a place where students with diabetes can talk to each other. This is especially important for freshmen who have never lived alone with the disease.

Schepers said she hopes the group can get upperclassmen to mentor underclassmen on how to live with diabetes in college. This includes learning how to handle the drinking culture as well as eating in the dining hall and regulating their blood pressure.

Students are given this freedom and they dont know what to do with it, Schepers said, Theyre thrown into this crazy culture and theyre not regulating it, and people around them dont know how to help them.

Jacinta Benton, a member of College Diabetes Network, said the group has supported her by being a place where she can have personal interactions with others who have Type 1 diabetes. Benton was diagnosed with the disease last year when she was a freshman.

Benton said she quickly learned to take diabetes one day at a time. She said she hopes students will be educated on the science behind diabetes. Benton also said she thinks its important for UNL students to know what to do in a situation when a diabetics blood pressure is too low or too high.

Students should know how to check a students blood pressure and when to give more sugar if its at dangerous levels, she said.

Benton said that reaching out to other people with diabetes helps you learn specific accommodations you can get in college.

I would recommend to people who get diagnosed to do your research and reach out to people early, she said. If you do it early, later on in your life its simpler - not easier - but simpler.

Schepers said she hopes the group can get the word out about College Diabetes Network and attract new members. She said in the future she wants students who get diagnosed to get sent straight to College Diabetes Network so they can help with the transition.

The club accepts students who have diabetes, students who know someone who has it or students who just want to help the cause. Schepers said to go to their Facebook page CDN-Lincoln to learn more about meeting times and upcoming events like an awareness campaign and their first annual Walk to Cure Diabetes on April 2 with a fraternity on campus, Delta Tau Delta.

Schepers said there is also a GoFundMe page for the event if someone cannot attend but would like to help.

We are very close to a cure for Type 1 right now, Alberts said. I think that cure can come in my brothers lifetime.

news@dailynebraskan.com

Excerpt from:
UNL's new College Diabetes Network hopes to raise awareness, connect students - Daily Nebraskan

Posted in Diabetes | Comments Off on UNL’s new College Diabetes Network hopes to raise awareness, connect students – Daily Nebraskan

D-backs’ De La Rosa counting on stem-cell therapy to avoid second Tommy John – Arizona Sports (registration) (blog)

Posted: March 6, 2017 at 2:46 am

Rubby De La Rosa had already undergone Tommy John surgery. So when his right elbow became an issue again, he had a tough decision to make.

He could have the surgery again and risk that it might not be as effective the second time around. Or he could venture down another avenue.

Either way, his career was at stake.

De La Rosa was in his second season as a Diamondback when it was interrupted in September by a familiar pain in his elbow.

His rookie season with the Dodgers in 2011 was cut short for the same reason. He ended up having his first Tommy John procedure.

So when the issue arose again last season, he and Dr. James Andrews who performed De La Rosas first Tommy John surgery discussed the options. They decided stem-cell therapy would be more effective than a second surgery. De La Rosa then received one stem cell injection in late September and another in December.

He has been playing catch and said he feels 100-percent healthy, but he will not begin throwing off the mound until mid-March.

What I see from it right now, its working, said De La Rosa, who will be 28 years old March 4. No more pain, no more soreness. Just waiting for my time.

Dr. Keith Jarbo is an orthopedic surgeon with OrthoArizona who specializes in elbow surgery. Jarbo, who has performed many Tommy John surgeries to repair the ulnar collateral ligament, said the procedure is less effective the second time around.

Stem-cell therapy has become more popular in orthopedics over the past five to 10 years, Jarbo said. Some doctors even use it in addition to Tommy John surgery to accelerate the healing process. He said stem cells are used because they are pluripotent, meaning they can develop into every type of cell that makes up the body.

They have a lot of the growth factors that are necessary for healing, Jarbo said. We think they can be important adjuncts for healing.

However, there is a risk. Jarbo said there is no research that compares the efficacy of stem-cell therapy to that of Tommy John surgery. With the lack of research, Jarbo said one doctor may be using different types of stem cells than another.

He said he doesnt use stem cells and wont until there is more research that shows it is effective. Until then, he cant assure his patients that stem-cell therapy will produce a ligament that has similar characteristics to what it did before the injury.

Its high-risk in the sense that we dont know exactly what its going to do, Jarbo said. We think that it promotes healing, but we dont know exactly what growth factors are within or whats going to happen.

I dont think youre necessarily getting a new, better tissue as if youre developing a robot. Youre really just trying to get good healing and strong appropriate tissue, whether thats with surgery or not.

Jarbo estimated Andrews conducts over 100 Tommy John surgeries per year. He said doctors like Andrews may be helpful in researching stem-cell therapys effectiveness if they can use stem cells on half of their patients and compare the results with the half that received Tommy John surgery.

De La Rosa is part of a group of trendsetters. Last season, Los Angeles Angels of Anaheim pitchers Garrett Richards and Andrew Heaney both received stem cell injections to stave off Tommy John surgery. Heaney ended up needing the surgery anyway.

D-backs manager Torey Lovullo said De La Rosa seems encouraged by his health.

We just know that Rubby is in a really good place, hes been throwing the ball really well hes smiling, and hes back to himself, which is always a good sign for him, he said.

Diamondbacks pitching coach Mike Butcher said stem-cell therapy is unpredictable, but seems to helping De La Rosa.

Its obviously helped out Rubby, Butcher said. The results have been good so far; he feels great. Now its just a matter of working toward the progression of where we can get him off the mound.

Jarbo said the largest risk with using stem-cell therapy may be that players are rushed back to action through an accelerated rehab program.

However, De La Rosa has been patient throughout his now five-month recovery.

He hopes it means the end of his elbow pain.

Its frustrating because sometimes you want to pitch but you cannot pitch because theres a lot of soreness, he said. When you do it right and you get hurt and everything switches, now you cant pitch with your whole motion and you have to limit a lot of things.

You get bad pitching.

The rest is here:
D-backs' De La Rosa counting on stem-cell therapy to avoid second Tommy John - Arizona Sports (registration) (blog)

Posted in Arizona Stem Cells | Comments Off on D-backs’ De La Rosa counting on stem-cell therapy to avoid second Tommy John – Arizona Sports (registration) (blog)

Trump’s coal council to drill down on advanced technology – Washington Examiner

Posted: March 6, 2017 at 2:45 am

President Trump's clean coal agenda could get some much-needed clarity as federal advisers take a hard look at advanced technologies to make coal plants more competitive and climate-friendly, as Trump's plan to repeal regulations will only go so far toward restoring the industry.

Some of the experts slated to lead the discussion at this year's spring meeting of the National Coal Council, a federal advisory committee, are skeptical about how much Trump can actually do over the next four years to help the coal industry beyond removing regulations.

Eliminating regulations is only a short-term remedy for what ails the coal industry. Removing Obama-era climate regulations would stop some of the planned coal plant retirements while allowing for the construction of newer, more efficient coal plants, which are considered a variant of clean coal technology.

Stay abreast of the latest developments from nation's capital and beyond with curated News Alerts from the Washington Examiner news desk and delivered to your inbox.

Sorry, there was a problem processing your email signup. Please try again later.

Processing...

Thank you for signing up for Washington Examiner News Alerts. You should receive your first alert soon!

Top consultants say the Trump agenda needs to be paired with a longer-term strategy that looks at more advanced technology such as carbon capture and storage, or CCS, which strips carbon pollution from coal plant emissions.

Amid Trump's promise to roll back climate change rules and withdraw from the Paris climate accord, much of the talk at the March 14-15 meeting will be on ways to make the coal industry more climate-friendly through the use of CCS. But even that isn't a sure fix, and it won't have job benefits for years to come, which is Trump's primary goal.

"I think everything that drives [Trump's] policy decisions is geared at the top level, first and foremost, to jobs," said Andy Roberts, research director for energy consultants Wood Mackenzie. "He wants to restore better economic health to the energy industry."

Roberts will deliver the keynote address, aptly named "Opportunities for Coal in the Trump Administration," at the coal council meeting, according to the official agenda.

When it comes to Trump's jobs priorities, Roberts doesn't see "clean coal" technologies that Trump continues to tout offering much in the way of putting miners back to work, at least not quickly.

Also from the Washington Examiner

"At the very least you can imagine them playing a provocative role," said Rep. Peter Roskam, R-Ill.,

03/06/17 12:01 AM

"In the short-term, that means unburdening the industry from regulations to the extent [coal] competes on a level playing field," Roberts said. But clean coal technologies, primarily carbon capture and storage, "don't really impact employment in the industry in the short term and medium term at all."

"It's not economic," Roberts added. "It's never going to be economic versus other forms of energy production." But it may still be necessary, he said, "depending on what the world decides it's going to do about topics like climate change."

That's why the primary thrust of the coal meeting will be focused on CCS and enhancing "the efficiency and emissions profile of our coal fleet," according to the agenda. However, the focus of the advisory panel in Trump's first year has not been determined, Janet Gellici, the National Coal Council's CEO, said before Rick Perry was confirmed as energy secretary Thursday. The coal council reports to the secretary.

The coal council under former President Barack Obama focused on legislative and policy recommendations for advancing CCS and even more advanced technologies that use the carbon to generate additional revenue stream for power plants.

One of the technologies that will be highlighted at this month's meeting will come from a company that has been collaborating with Exxon Mobil to commercialize a form of CCS technology for reducing emissions at natural gas power plants. The company sees fuel cells as a solution to the next big challenge for cutting carbon dioxide emissions, which is anticipated to be focused on natural gas power plants.

Also from the Washington Examiner

With Trump in the White House and a GOP Congress, financial firms are well-positioned for looser regulation.

03/06/17 12:01 AM

Currently, natural gas-fired plants are taking market share from coal, since they release 60 percent fewer emissions than coal plants. Gas plants, according to Exxon Mobil, are the reason the nation's emissions are at their lowest in 25 years.

Nevertheless, any advancements in cutting carbon pollution further will stem from advancements that will come from developing CCS at coal plants, said officials with the company FuelCell Energy, which is collaborating with Exxon on CCS. Capturing carbon from natural gas is slightly different than capturing it from coal, but advancements on either would help the other fuel.

Officials with FuelCell Energy will be discussing its projects with the Energy Department, as well as the joint venture it has with Exxon. They say Trump's focus on manufacturing is good for clean coal, but also for cleaner forms of natural gas that they anticipate being needed further down the road.

"One aspect that we're certainly encouraged with is the focus on American manufacturing," said Kurt Goddard, head of investor relations for the company. "Because fuel cells represent American innovation, they represent American manufacturing."

Fuel cells had support in previous Republican administrations. Former president George W. Bush created the hydrogen fuel cell initiative to wean the nation off its "addiction to oil." But it's not clear if Trump might do something similar.

Fuel cells are a highly efficient means of producing electricity. Rather than burning a fuel, like a standard power plant does, they produce electricity through a chemical process using an electrolyte similar to a battery. But instead of charging it as a battery, the electrolyte is refilled. FuelCell Energy's device concentrates the carbon dioxide from a coal-fired power plant as part of its electricity-generation process. The process reduces carbon emissions and other pollutants.

It's also a form of clean energy that is completely made in America, Goddard said. "Our manufacturing facility is actually in Connecticut, whereas some other forms of clean power generation aren't necessarily made in the U.S.," he said, explaining why he believes Trump is supportive of CCS. It's a technology that is evolving, he said, with interest coming from Exxon, the Canadian oil sands and Europe.

Anthony Leo, the company's vice president for technology and applications, will discuss its fuel cell clean coal project at this month's meeting, in addition to the natural gas work he is doing with Exxon Mobil. The coal and gas projects are both being done at Southern Co.'s Barry Plant in Alabama.

The projects are in the engineering phase, with construction not expected to begin for about two years. Exxon CEO Darren Woods underscored the project in a blog post last month.

"Our role as the country's largest producer of natural gas which emits up to 60 percent less CO2 than coal for power generation has helped bring CO2 emissions in the United States to the lowest level since the 1990s," said Woods, who took over after predecessor Rex Tillerson was appointed secretary of state.

"But the world also will need breakthrough clean-energy technologies such as carbon capture and storage," he said, noting that the company is "investing heavily in CCS, including research in a novel technology that uses fuel cells that could make CCS more affordable and expand its use."

An Exxon official emphasized to the Washington Examiner that the company's piece of the project has received no funding or support from the government.

Roberts observed that the future of CCS could very well resemble what is being demonstrated between the fuel cell company and Exxon. He also said the "model" for clean coal could follow what is happening between SpaceX and NASA, where a private company "is driving a lot of our national space exploration activities, right now, at the direction of NASA but with cooperation."

Roberts sees demand for clean coal technology coming from Europe, where the continent's climate change policies require the technologies, even if Trump succeeds in exiting from the Paris climate agreement.

"Maybe if the U.S. steps back for a while, the driving factors happen in Europe," Roberts said.

Coal use is projected to grow globally, and there will be an increasing need for coal power plants to be made more efficient and with fewer emissions, said Benjamin Sporton, the head of the World Coal Association. He was in Washington last month to discuss advancements on coal technology with congressional staffers.

He was also in the U.S. as part of an International Energy Agency industry advisory team meeting with coal companies to get a sense of where they are on technology development, he told the Washington Examiner in an interview.

"For me it's a continuum," he said. "It's not saying let's leap to CCS today, because CCS is not a technology that is viable for widescale deployment today. It's about saying how we start on that pathway to get to somewhere further down the track."

Expanding federal incentives for carbon capture technologies was an idea supported by both parties last year. And a lobbying push by unlikely bedfellows, major coal companies and environmentalists, is gaining steam to move a similar bill in this Congress.

"When utilities, coal companies and environmental groups come together to support your bill, you know you're onto something that could work," Democratic Sen. Heidi Heitkamp of North Dakota said last year in introducing her bill to expand the coal incentives. Senate Majority Leader Mitch McConnell of Kentucky was a co-sponsor of the legislation.

More here:
Trump's coal council to drill down on advanced technology - Washington Examiner

Posted in Alabama Stem Cells | Comments Off on Trump’s coal council to drill down on advanced technology – Washington Examiner

WATCH: Helping farmers through agricultural biotechnology – Rappler – Rappler

Posted: March 6, 2017 at 2:45 am

The UP Genetic Researchers and Agricultural Innovators Society strives to uphold awareness on the ways, means, and science behind agricultural biotechnology to help students and farmers alike

Published 6:59 AM, March 06, 2017

Updated 9:19 AM, March 06, 2017

MANILA, Philippines How can agricultural biotechnology help and serve farmers and students alike?

These students from the University of the Philippines Genetic Researchers and Agricultural Innovators Society or UP GRAINS found a way.

We think its important to promote biotechnology because its one of the most advanced fields of science and we think it is also neglected in the Philippines," founding Vice-President of UP Grains Kohlin Lallaban said.

UP GRAINS, which was formed in 2014 in UP Los Baos, is an academic organization that promotes agricultural biotechnology. The group helps farmers make a living. Its programs allow students from Batangas, Laguna, and Camarines Norte provinces learn about techniques in biotechnology and how they can apply these to their research.

They bring experts and professors from different universities in Laguna and Batangas to communities, teaching farmers how to grow their crops better.

The student organization has touched lives through its programs which include academic tutorials (Chem 40: Basic Organic Chemistry Tutorials), educational discussions (AgriBioTalk Series), inter-high school information drives (Lakbay-Bioteknolohiya Workshops), farmer-oriented extension programs (Ugnayan Series), interactive advocacy campaigns (#EveryButilCounts, Free Demo Shirt Printings), and even a nationwide junior research conference (Project BT).

There was this one time that we did an extension activity in Laguna. We pushed the farmers to establish an irrigation system for their farm. Right now, theyre producing almost 40% more of cavans of rice than they were able to produce before, Lallaban shared.

One of the greatest ironies in the Philippines is that food producers like farmers and fishermen are the most vulnerable to hunger. UP GRAINS wants to change this situation in rural communities. By change, they mean continuous innovation for a better future, according to Lallaban.

"We think that the biggest lesson that our organization learned from our immersions is that there are bigger things than us, there are bigger things that we have to do, there are bigger things that we have to think about and that there is no better time to do that than now." Rappler.com

UP GRAINS is a partner organization of Rappler's civic engagement arm MovePH. For more information on how you can help or be part of UP GRAINS, check out their stories on X. Know more about our other organization partners:

Do you want your organization to be part of MovePH's X Network? Email us at move.ph@rappler.com!

At Rappler, we believe there are many freedoms: to speak, to choose, to love, or just to be. #InspireCourage is our campaign to encourage people to speak up, engage in issues, and continue fighting for the change they want to see. Be part of the conversation

See the article here:
WATCH: Helping farmers through agricultural biotechnology - Rappler - Rappler

Posted in Biotechnology | Comments Off on WATCH: Helping farmers through agricultural biotechnology – Rappler – Rappler

Why Puma Biotechnology Inc. Got Hammered Today – Motley Fool

Posted: March 6, 2017 at 2:45 am

What happened

Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed "Aphinity."

Image source: Getty Images.

In Roche's trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy, and then took Perjeta and Herceptin, or just Herceptin, for an additional year. Roche didn't release the full data from the clinical trial, but it did say the triple combination reduced the risk of recurrence of invasive disease or death compared to Herceptin and chemotherapy alone.

The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.

Without any data, doctors will likely wonder whether neratinib helps patients that have received Herceptin and Perjeta. And the relapse rate for patients on the current standard of care is already quite low; if adding Perjeta decreases it further, doctors and their patients may decide taking another drug after that isn't worth it, especially given neratinib's side-effect profile.

Investors will have to wait for the full data from Aphinity -- perhaps at the American Society of Clinical Oncology meeting in June -- to know how much better Herceptin plus Perjeta is than Herceptin alone, and how that might affect neratinib's sales, assuming it's approved later this year.

Brian Orelliand The Motley Fool have no positions in any of the stocks mentioned. The Motley Fool has adisclosure policy.

More here:
Why Puma Biotechnology Inc. Got Hammered Today - Motley Fool

Posted in Biotechnology | Comments Off on Why Puma Biotechnology Inc. Got Hammered Today – Motley Fool

Thursday’s Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) – Smarter Analyst

Posted: March 6, 2017 at 2:45 am

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares skyrocketed over 65% this morning, after the drug maker announced top-line results from its AURA-LV Phase IIb study with voclosporin (VCS) in patients with lupus nephritis (LN) that showed at 48 weeks, the study met its complete remission (CR) and partial remission (PR) endpoints.

FBR analyst Vernon T. Bernardino commented, We are impressed with the results, as CRs and PRs at 48 weeks exceeded CRs and PRs at 24 weeks, with one exception. As a reminder, each study arm included standard of care mycophenolate mofetil (MMF) as background therapy and a forced steroid taper. There were no unexpected safety signals or deaths observed in VCS-treated patients. Thus, in addition to strong efficacy, VCS appears to allow safe steroid sparing. We think the results are robust and bode well for a successful Phase III trial, which could make VCS the first approved therapy for LN.

As of this writing,the 4 analysts polled by TipRanks (in the past 6months) rate Aurinia stock a Buy. With a return potential of 39%, the stocks consensus target price stands at $8.50.

Puma Biotechnology Inc (NASDAQ:PBYI) shares lost one-quarter of their value today, after competitor Roche announced positive top-line results from the highly anticipated APHINITY trial,which explores usefulness of Perjeta in adjuvant breast cancer. Recall, Puma has US/EU regulatory applications under review for neratinib in the extended adjuvant setting based on positive Phase 3 ExteNET data.

J.P Morgan Cory Kasimov commented, Todays PR is expectedly light on details, so well have to wait for ASCO to get the full picture. In our view, the future of neratinib in this indication largely rests on the nuances of the data, namely: 1) the magnitude of benefit, 2) the subgroups that drive this benefit (HR+ and/or HR-), and 3) details of the safety profile. The ultimate impact on Puma remains to be seen, but this outcome has obviously taken the near-term best-case scenario off the table. Our prevailing expectation was that on positive APHINITY results, PBYI shares could initially lose roughly 1/3 of their value. That said, investor feedback weve been getting has suggested that this potential dip could provide an opportunity ahead of the ASCO details as well as a number of pending neratinib data points in 1H17.

Out of the 8 analysts polled by TipRanks (in the past 12 months), 6 rate Puma Biotechnology stock a Buy, while 2 rate the stock a Hold. With a return potential of 180%, the stocks consensus target price stands at $79.

Read the original post:
Thursday's Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) - Smarter Analyst

Posted in Biotechnology | Comments Off on Thursday’s Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) – Smarter Analyst

Diabetes Smackdown seminar – Kozi Radio

Posted: March 6, 2017 at 2:43 am

Chelan / Manson: 93.5 FM 100.9 FM 1230AM | Manson / Brewster / Pateros / Methow: 103.1 FM

Take Back Your Health And Your Life!

Learn How to Take Control And Beat Diabetes

Take back your health and transform your life! Diabetes Smackdown is a groundbreaking seminar that reveals exactly what is stopping you in your life. You will experience a new freedom as you create empowering and lasting behaviors in the area of your health.

Join us at the Diabetes Smackdown seminar and learn

This is not a pill, shake, or supplement. This is the ultimate way to manage your diabetes and learn how to create health and vitality. This is hope.

Join us on March 11 & 12 to be part of the movement to reverse the Diabetes trend.

Chelan Seminar

When: March 11-12, 2017 Time: Saturday 8:00am to 6:00pm and Sunday 8:30 a.m. to noon. Where: 232 E Wapato Ave,Chelan WA 98816 Fee: $125 Food: Lunch and hearty snacks are included

Proudly Sponsored by Lake Chelan Community Hospital Foundation

We've worked out deals with some of our area's best restaurants and businesses!

2016 Icicle Broadcasting, Inc. | All Rights Reserved

Read more:
Diabetes Smackdown seminar - Kozi Radio

Posted in Diabetes | Comments Off on Diabetes Smackdown seminar – Kozi Radio

A Diabetes Mom’s Thoughts on the Horrific Murder of Alex Radita – A Sweet Life (blog)

Posted: March 6, 2017 at 2:43 am

Of all the photos taken over 20 years of my daughter Laurens diabetes life, the one that haunts me is the one in which she and we had no idea Type 1 diabetes was trying to kill her.

Its her formal kindergarten picture, taken in 1997, when, sans Internet, youd have your school picture taken and six weeks later it would be sent home. In my daughters picture shes gaunt and pale in a way that I somehow didnt notice in daily living. Her cute dresss shoulder seam sits almost at her elbow. Shed grown so thin, her clothes were almost falling off of her.

I didnt understand what was happening.

Id been semi-nonchalantly rationalizing her symptoms (excessive, nearly unquenchable thirst = it was a particularly warm fall; everyone was thirsty). Bed-wetting (shed just started school, stress perhaps?) Weight loss. (She was growing taller. Her dad was thin. Id been thin almost all my life). When I finally brought her to the doctor and they made the diagnosis, I realized it had all been right there before me.

After my daughters diagnosis I was so absorbed with her care that I hardly reflected on what it had been like before the diagnosis. Six weeks later, my heart nearly broke when her school picture arrived in the mail. It was taken two days before her Type 1 diabetes diagnosis.

I will always harbor a tiny bit of guilt for not seeing my daughters suffering before her diagnosis.I was reminded of Laurens kindergarten picture when I read that after a months-long trial, a Canadian judge has found Emil and Rodica Radita guilty of first-degree murder in the death of their 15 year old son, Alex, who had Type 1 diabetes. The Raditas denied their son the insulin therapy he needed to survive, and were both sentenced to life in prison.

The Washington Post reports:

An emergency worker detailed thedisturbing scene upon discovering the teen in his parents bedroom on the night of his death, May 7, 2013.

She described him as emaciated to the point where he appeared mummified. His face had no visible flesh left as she could see every bone in his face, court records of the workers account stated. He had black, necrotic sores on his face and his left jaw had open sores so deep she could see his jaw bone. There was nothing left of his stomach as he was just so extraordinarily skinny. She estimated his waistline to be approximately three inches. He was dressed in a diaper and t-shirt. His eyes were open. He was not breathing.

An autopsy foundthecause of death to bebacterial sepsis, brought on by starvation and neglect.

Every parent should be horrified by this story letting a child in your care die of a treatable disease because of religion? And for the diabetes-parent, it goes much deeper because weve been with our children through many high blood sugar experiences. Weve smelled the sickly-sweet poison of ketones on our kids breath. We know first-hand just how evil diabetes can be to a body, even when care is present. We understand this because we are so intimate with the disease. The cruelty of Alexandru Raditas murder, then, the years of his unthinkable suffering and horror, shreds our hearts in a kind of personal way because we spend our lives making sure that never happens to our children.

Court records state that the Raditas took Alex, who was diagnosed with Type 1 diabetes in 2000, to the hospital in 2003 and told the doctor he had only been sick for a couple of weeks when he got a viral infection and began vomiting. The doctor could not reconcile this information to the physical state Alex was then in. He asked Mrs. Radita directly whether she understood that Alex had diabetes. She did not respond.

In 2004, Alex was placed in foster care where he thrived, learning the basics of his diabetes care like matching the food he ate with a dose of insulin, and understanding the importance of constant oversight and care.

But in 2005 he was sent back to his parents. Four years later the Raditas moved to Alberta, where Alex was reportedly homeschooled, and isolated from anyone who could see his sickly condition and interfere on his behalf. Alex lived and died alone, a prosecutor said.

The Raditas withheld simple shots of insulin from their son, shots which take only 10 seconds to administer, and which enable a person with diabetes to live a full, healthy, and happy life. Instead they chose to let him sink into what had to have been one of the most horrifying and painful deaths imaginable.

When I look at that photo of my daughter, suffering greatly and me not knowing yet, I flash back to something someone said after her diagnosis that bothered me then.

Im glad she has you for a mom.

How I wish Alex had been mine, or the child of one of the thousands and thousands of D-parents I know who would turn their lives upside down to make his better.

The image of Alex Radita is a screenshot from the Calgary Heralds report.

See original here:
A Diabetes Mom's Thoughts on the Horrific Murder of Alex Radita - A Sweet Life (blog)

Posted in Diabetes | Comments Off on A Diabetes Mom’s Thoughts on the Horrific Murder of Alex Radita – A Sweet Life (blog)

Stem Cell Therapy – Premier Regenerative Stem Cell

Posted: March 5, 2017 at 9:44 am

The Re-Brand Premier Regenerative Stem Cell and Wellness Centers, recently rebranded their business from Premier Stem Cell Institute, in response to expanding locations, technology, and treatments. This move reflects the growth and success this company has undergone recently and goals for the future.

PRSC and Wellness Centers President, Kandace Stolz said, This rebrand is the culmination of the years of work weve put into stem cell medicine. Were growing and healing more patients than we ever have before, this new name reflects those accomplishments and gives us room grow. We are so thrilled for this move and cant wait to do even more for our patients going forward.

Premier Regenerative Stem Cell and Wellness Centers will continue to partner with the NFL Alumni Association and treat current and former professional athletes. PRSC remains dedicated to studying stem cell treatment by collecting and tracking data to further stem cell progress and maximize results for all patients. PRSCs commitment to being a leader in stem cell and regenerative medicine is unwavering and will continue to innovate and learn to heal and improve the quality of life for all patients.

About Premier Regenerative Stem Cell and Wellness Centers: PRSC is a leading research and treatment facility in Colorado, providing innovative medicine and therapies for those in pain by harnessing the bodys own natural healing power of stem cells. As team of cutting-edge medical experts, PRSC is dedicated to treating patients by using their own stem cells to heal, improve quality of life, and battle the acute pain of chronic illnesses. Premier Regenerative Stem Cell and Wellness Center locations include Loveland Colorado, Dallas Texas, St. Louis, Missouri, and Jacksonville, Florida. PRSC has plans to expand to other major cities across the United States in the near future.

Read the original:
Stem Cell Therapy - Premier Regenerative Stem Cell

Posted in Colorado Stem Cells | Comments Off on Stem Cell Therapy – Premier Regenerative Stem Cell

New gene therapy for cancer shows promise in major test – Colorado Springs Gazette

Posted: March 5, 2017 at 9:44 am

In this May 2016 photo provided by Kite Pharma, cell therapy specialists at the company's manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. The experimental gene therapy, called CAR-T cell, turns a patient's own blood cells into specialized cancer killers and worked in the study, with more than one third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday, Feb. 28, 2017. (Kite Pharma via AP)

An experimental gene therapy that turns a patient's own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.

In all, 82 percent of patients had their cancer shrink at least by half at some point in the study.

Its sponsor, California-based Kite Pharma, is racing Novartis AG to become the first to win approval of the treatment, called CAR-T cell therapy, in the U.S. It could become the nation's first approved gene therapy.

A hopeful sign: the number in complete remission at six months 36 percent is barely changed from partial results released after three months, suggesting this one-time treatment might give lasting benefits for those who do respond well.

"This seems extraordinary ... extremely encouraging," said one independent expert, Dr. Roy Herbst, cancer medicines chief at the Yale Cancer Center.

The worry has been how long Kite's treatment would last and its side effects, which he said seem manageable in the study. Follow-up beyond six months is still needed to see if the benefit wanes, Herbst said, but added, "this certainly is something I would want to have available."

The therapy is not without risk. Three of the 101 patients in the study died of causes unrelated to worsening of their cancer, and two of those deaths were deemed due to the treatment.

It was developed at the government's National Cancer Institute and then licensed to Kite. The Leukemia and Lymphoma Society helped sponsor the study.

Results were released by the company and have not been published or reviewed by other experts. Full results will be presented at the American Association for Cancer Research conference in April.

The company plans to seek approval from the U.S. Food and Drug Administration by the end of March and in Europe later this year.

The treatment involves filtering a patient's blood to remove key immune system soldiers called T-cells, altering them in the lab to contain a gene that targets cancer, and giving them back intravenously. Doctors call it a "living drug" permanently altered cells that multiply in the body into an army to fight the disease.

Patients in the study had one of three types of non-Hodgkin lymphoma, a blood cancer, and had failed all other treatments. Median survival for such patients has been about six months.

Kite study patients seem to be living longer, but median survival isn't yet known. With nearly nine months of follow-up, more than half are still alive.

Six months after treatment, 41 percent still had a partial response (cancer shrunk at least in half) and 36 percent were in complete remission (no sign of disease).

"The numbers are fantastic," said Dr. Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study and has been a paid adviser to Kite. "These are heavily treated patients who have no other options."

One of his patients, 43-year-old Dimas Padilla of Orlando, was driving when he got a call saying his cancer was worsening, chemotherapy was no longer working, and there was no match to enable a second try at a stem cell transplant.

"I actually needed to park ... I was thinking how am I going to tell this to my mother, my wife, my children," he said. But after CAR-T therapy last August, he saw his tumors "shrink like ice cubes" and is now in complete remission.

"They were able to save my life," Padilla said.

Of the study participants, 13 percent developed a dangerous condition where the immune system overreacts in fighting the cancer, but that rate is lower than in some other tests of CAR-T therapy. The rate fell during the study as doctors got better at detecting and treating it sooner.

Roughly a third of patients developed anemia or other blood-count-related problems, which Locke said were easily treated. And 28 percent had neurological problems such as sleepiness, confusion, tremor or difficulty speaking, but these typically lasted just a few days, Locke said.

"It's a safe treatment, certainly a lot safer than having progressive lymphoma," and comparable to combination chemotherapy in terms of side effects, said the cancer institute's Dr. Steven Rosenberg, who had no role in Kite's study. The first lymphoma patient Rosenberg treated this way, a Florida man, is still in remission seven years later.

There were no cases of swelling and fluid in the brain in this or any other study testing Kite's treatment, company officials said. That contrasts with Juno Therapeutics, which has had a CAR-T study put on hold twice after five patient deaths due to this problem.

Company officials would not say what the treatment might cost, but other types of immune system therapies have been very expensive. It's also being tested for some other types of blood cancer.

___

Online:

Lymphoma info: http://seer.cancer.gov/statfacts/html/nhl.html

CAR-T therapy: http://www.cancer.gov/about-cancer/treatment/research/car-t-cells

Gene therapy: http://ghr.nlm.nih.gov/primer/therapy/availability

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP .

Read the rest here:
New gene therapy for cancer shows promise in major test - Colorado Springs Gazette

Posted in Colorado Stem Cells | Comments Off on New gene therapy for cancer shows promise in major test – Colorado Springs Gazette

Page 1,651«..1020..1,6501,6511,6521,653..1,6601,670..»